Pfizer Inc (NYSE:PFE)'s shares remained unmoved as its fourth-quarter result beat the Street by showing a surprise profit. For the three months ended December 31, the drugs giant reported earnings ...

Pfizer (PFE) shares are on the move after posting a mixed fourth-quarter earnings report, with adjusted earnings topping expectations, but missing revenue estimates. The pharmaceutical giant saw a ...

Pfizer Inc (NYSE:PFE) entered the earnings ring before the bell this morning, announcing fourth-quarter earnings of 10 cents per share, which is higher than analysts' anticipated losses of 22 cents.

Pfizer Inc. (PFE) delivered a surprise profit in the fourth quarter despite a double-digit contraction in revenue. Pfizer shares were up 1.8% in early trading Tuesday following the release.

Pfizer (PFE) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of a loss of $0.19 per share. This compares to earnings of $1.14 per share a year ago.

Geoff Meacham, Bank of America Securities senior pharmaceuticals analyst, joins 'Squawk Box' to break down Pfizer's quarterly earnings results, Big Pharma 2024 outlook, and more.

CNBC's Mike Santoli reports on the company's quarterly earnings results.

Shares of Pfizer Inc. PFE, +0.04% gained 0.7% early Tuesday after the company beat analysts' earnings expectations and reaffirmed its full-year 2024 guidance issued in December.

Pfizer reversed roughly $3.5 billion in revenue related to the expected return of 6.5 million doses of its Covid drug, Paxlovid, from the U.S. government.

Pharmaceutical giant Pfizer on January 30th reported its financial results for Q4 and the full year of 2023. The company reported disappointing results, to say the least, including $58.5 billion in...

Pfizer reported a surprise quarterly profit on Tuesday, as COVID products demand was better than the company's expectations and research costs declined.

Investor focus is likely to be on the sales numbers of Pfizer's (PFE) several newly launched drugs like Abrysvo, Velsipity, Penbraya as well as newly acquired products like Nurtec and Oxbryta on th...

The defensive names, characterized by their immunity to the business cycle, in the market could soon see an inflow of investment dollars not seen since the last wave of the business cycle. This tim...

Pfizer has reached a transition point as sales of its top products decline. But the company is completing its biggest string of new product launches, a move to spur a new phase of growth.

Analysts are projecting another difficult quarter for Pfizer Inc. (PFE) in which the company likely suffered a steep drop in revenue as demand for its COVID-19 products declined.